Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials

For many years, multiple sclerosis (MS) was believed to be a disease seen almost solely in White people. However, mounting evidence has made it clear that non-White individuals are equally, if not more frequently and severely, affected by MS than their White counterparts.1,2 Perhaps both a contributor to and consequence of this racial myth is the fact that non-White persons with MS are dramatically underrepresented in MS clinical trials. There is a pressing need to evaluate whether clinical trials are reflective of the diverse population that is affected by MS.

Read article at journal's website

Related Articles


Your email address will not be published.